Candel Therapeutics, Inc. Cash Flow Statement
CADL|3 years of annual SEC 10-K data (FY2021-FY2023)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
Candel Therapeutics, Inc. used $34M in operating cash flow and negative free cash flow of $35M in FY2023.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2023 | FY2022 | FY2021 |
|---|---|---|---|
| Net Income | -$37.9M | -$36.1M | -$17.7M |
| Depreciation & Amortization | - | $232.0K | $91.0K |
| Operating Cash Flow | -$34.2M | -$22.2M | -$9.1M |
| Capital Expenditures | $457.0K | $1.8M | $1.5M |
| Free Cash Flow | -$34.7M | -$24.1M | -$10.5M |
| FCF Margin | - | -19242.4% | -8437.6% |